Literature DB >> 24971483

Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout.

H Ehlken1, S Krishna-Subramanian2, L Ochoa-Callejero3, V Kondylis2, N E Nadi2, B K Straub4, P Schirmacher4, H Walczak5, G Kollias6, M Pasparakis2.   

Abstract

Hepatocellular carcinoma (HCC) usually develops in the context of chronic hepatitis triggered by viruses or toxic substances causing hepatocyte death, inflammation and compensatory proliferation of liver cells. Death receptors of the TNFR superfamily regulate cell death and inflammation and are implicated in liver disease and cancer. Liver parenchymal cell-specific ablation of NEMO/IKKγ, a subunit of the IκB kinase (IKK) complex that is essential for the activation of canonical NF-κB signalling, sensitized hepatocytes to apoptosis and caused the spontaneous development of chronic hepatitis and HCC in mice. Here we show that hepatitis and HCC development in NEMO(LPC-KO) mice is triggered by death receptor-independent FADD-mediated hepatocyte apoptosis. TNF deficiency in all cells or conditional LPC-specific ablation of TNFR1, Fas or TRAIL-R did not prevent hepatocyte apoptosis, hepatitis and HCC development in NEMO(LPC-KO) mice. To address potential functional redundancies between death receptors we generated and analysed NEMO(LPC-KO) mice with combined LPC-specific deficiency of TNFR1, Fas and TRAIL-R and found that also simultaneous lack of all three death receptors did not prevent hepatocyte apoptosis, chronic hepatitis and HCC development. However, LPC-specific combined deficiency in TNFR1, Fas and TRAIL-R protected the NEMO-deficient liver from LPS-induced liver failure, showing that different mechanisms trigger spontaneous and LPS-induced hepatocyte apoptosis in NEMO(LPC-KO) mice. In addition, NK cell depletion did not prevent liver damage and hepatitis. Moreover, NEMO(LPC-KO) mice crossed into a RAG-1-deficient genetic background-developed hepatitis and HCC. Collectively, these results show that the spontaneous development of hepatocyte apoptosis, chronic hepatitis and HCC in NEMO(LPC-KO) mice occurs independently of death receptor signalling, NK cells and B and T lymphocytes, arguing against an immunological trigger as the critical stimulus driving hepatocarcinogenesis in this model.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24971483      PMCID: PMC4211370          DOI: 10.1038/cdd.2014.83

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  35 in total

1.  Hepatocyte-specific expression of Cre recombinase.

Authors:  C Kellendonk; C Opherk; K Anlag; G Schütz; F Tronche
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

Review 2.  Obesity, inflammation, and liver cancer.

Authors:  Beicheng Sun; Michael Karin
Journal:  J Hepatol       Date:  2011-11-25       Impact factor: 25.083

3.  Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality.

Authors:  T S Doi; M W Marino; T Takahashi; T Yoshida; T Sakakura; L J Old; Y Obata
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.

Authors:  Conor Mc Guire; Thomas Volckaert; Uta Wolke; Mozes Sze; Riet de Rycke; Ari Waisman; Marco Prinz; Rudi Beyaert; Manolis Pasparakis; Geert van Loo
Journal:  J Immunol       Date:  2010-11-10       Impact factor: 5.422

5.  Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice.

Authors:  D Rudolph; W C Yeh; A Wakeham; B Rudolph; D Nallainathan; J Potter; A J Elia; T W Mak
Journal:  Genes Dev       Date:  2000-04-01       Impact factor: 11.361

6.  Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.

Authors:  Filip Van Hauwermeiren; Marietta Armaka; Niki Karagianni; Ksanthi Kranidioti; Roosmarijn E Vandenbroucke; Sonja Loges; Maarten Van Roy; Jan Staelens; Leen Puimège; Ajay Palagani; Wim Vanden Berghe; Panayiotis Victoratos; Peter Carmeliet; Claude Libert; George Kollias
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

Review 7.  Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases.

Authors:  Manolis Pasparakis
Journal:  Nat Rev Immunol       Date:  2009-11       Impact factor: 53.106

8.  TNFR1 determines progression of chronic liver injury in the IKKγ/Nemo genetic model.

Authors:  F J Cubero; A Singh; E Borkham-Kamphorst; Y A Nevzorova; M Al Masaoudi; U Haas; M V Boekschoten; N Gassler; R Weiskirchen; M Muller; C Liedtke; C Trautwein
Journal:  Cell Death Differ       Date:  2013-08-09       Impact factor: 15.828

9.  A lymphotoxin-driven pathway to hepatocellular carcinoma.

Authors:  Johannes Haybaeck; Nicolas Zeller; Monika Julia Wolf; Achim Weber; Ulrich Wagner; Michael Odo Kurrer; Juliane Bremer; Giandomenica Iezzi; Rolf Graf; Pierre-Alain Clavien; Robert Thimme; Hubert Blum; Sergei A Nedospasov; Kurt Zatloukal; Muhammad Ramzan; Sandra Ciesek; Thomas Pietschmann; Patrice N Marche; Michael Karin; Manfred Kopf; Jeffrey L Browning; Adriano Aguzzi; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

Review 10.  Molecular mechanisms of hepatic apoptosis.

Authors:  K Wang
Journal:  Cell Death Dis       Date:  2014-01-16       Impact factor: 8.469

View more
  14 in total

Review 1.  Finding a new role for NEMO: A key player in preventing hepatocyte apoptosis and liver tumorigenesis by inhibiting RIPK1.

Authors:  I-Fang Hsin; Erica Montano; Ekihiro Seki
Journal:  Hepatology       Date:  2016-05-31       Impact factor: 17.425

2.  RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.

Authors:  Santosh Krishna-Subramanian; Stephan Singer; Marietta Armaka; Jesus M Banales; Kerstin Holzer; Peter Schirmacher; Henning Walczak; George Kollias; Manolis Pasparakis; Vangelis Kondylis
Journal:  Cell Death Differ       Date:  2019-04-15       Impact factor: 15.828

3.  RIPK1 protects from TNF-α-mediated liver damage during hepatitis.

Authors:  Aveline Filliol; Claire Piquet-Pellorce; Jacques Le Seyec; Muhammad Farooq; Valentine Genet; Catherine Lucas-Clerc; John Bertin; Peter J Gough; Marie-Thérèse Dimanche-Boitrel; Peter Vandenabeele; Mathieu Jm Bertrand; Michel Samson
Journal:  Cell Death Dis       Date:  2016-11-10       Impact factor: 8.469

Review 4.  Exploitation of Apoptotic Regulation in Cancer.

Authors:  David S Ucker; Jerrold S Levine
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

5.  The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis.

Authors:  Yutaka Shimizu; Nieves Peltzer; Alexandra Sevko; Elodie Lafont; Aida Sarr; Helena Draberova; Henning Walczak
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

Review 6.  NF-κB Members Left Home: NF-κB-Independent Roles in Cancer.

Authors:  Carlota Colomer; Laura Marruecos; Anna Vert; Anna Bigas; Lluis Espinosa
Journal:  Biomedicines       Date:  2017-05-25

7.  Disruption of the FasL/Fas axis protects against inflammation-derived tumorigenesis in chronic liver disease.

Authors:  Francisco Javier Cubero; Marius Maximilian Woitok; Miguel E Zoubek; Alain de Bruin; Maximilian Hatting; Christian Trautwein
Journal:  Cell Death Dis       Date:  2019-02-08       Impact factor: 8.469

8.  Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis.

Authors:  Trieu-My Van; Apostolos Polykratis; Beate Katharina Straub; Vangelis Kondylis; Nikoletta Papadopoulou; Manolis Pasparakis
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

9.  NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.

Authors:  Vangelis Kondylis; Apostolos Polykratis; Hanno Ehlken; Laura Ochoa-Callejero; Beate Katharina Straub; Santosh Krishna-Subramanian; Trieu-My Van; Harald-Morten Curth; Nicole Heise; Falk Weih; Ulf Klein; Peter Schirmacher; Michelle Kelliher; Manolis Pasparakis
Journal:  Cancer Cell       Date:  2015-11-09       Impact factor: 31.743

10.  The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.

Authors:  Torsten Hartwig; Antonella Montinaro; Silvia von Karstedt; Alexandra Sevko; Silvia Surinova; Ankur Chakravarthy; Lucia Taraborrelli; Peter Draber; Elodie Lafont; Frederick Arce Vargas; Mona A El-Bahrawy; Sergio A Quezada; Henning Walczak
Journal:  Mol Cell       Date:  2017-02-16       Impact factor: 19.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.